Establishment of a Langerhans cell histiocytosis lesion cell line with dermal dendritic cell characteristics

ICHIRO MURAKAMI¹, JEAN GOGUSEV², FRANCIS JAUBERT³, MICHIKO MATSUSHITA⁴, KAZUHIKO HAYASHI¹, IKUO MIURA⁵, TAKEHIRO TANAKA⁶, TAKASHI OKA⁷ and TADASHI YOSHINO⁷

¹Division of Molecular Pathology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8503, Japan; ²Inserm U507 and U1016, Institut Cochin, 75014 Paris; ³University of Paris Descartes (Paris V), 75006 Paris, France; ⁴Department of Pathobiological Science and Technology, School of Health Science, Faculty of Medicine, Tottori University, Yonago 683-8503; ⁵Division of Hematology and Oncology, St. Marianna University School of Medicine Hospital, Kawasaki, Kanagawa 216-8511; ⁶Department of Pathology, Okayama University Hospital, Okayama 700-8530; ⁷Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8530, Japan

Received July 7, 2014; Accepted October 2, 2014

DOI: 10.3892/or.2014.3567

Abstract. A cell line named PRU-1, derived from a Langerhans cell (LC) histiocytosis (LCH) skull lesion of a 7-year-old boy, was established and characterized. PRU-1 is an adherent spindle-shaped cell line that shows no Birbeck granules on electron microscopy. Flow cytometric analysis of cells collected from the early seventh passage showed no LC phenotypes of CD1a and S100 protein. Immunostaining of PRU-1 cells also revealed no expression of LC markers but showed expression of CD11c, CD54 (ICAM-1) and CD68, which was also observed in some peripherally located cells of the original LCH lesion. The PRU-1 cells stained positive for factor XIIIa and negative for CD34, suggesting a dermal dendritic cell phenotype. Cytogenetic analyses revealed abnormalities such as 39,XY,-2,-4,-8,-12,-12,-14,add(18)(q21),20,+mar and 44,XY,-11,-14,add(18)(q21). TCRγ rearrangement in the PRU-1 cells was not amplified by PCR. Tumorigenicity was not proven by xenografting into SCID mice. A conditioned medium from PRU-1 culture induced the proliferation of peripheral blood lymphocytes as well as the activation of monocytes from a healthy donor into CD1a-positive LC-like cells. Because the phenotypic characteristics of PRU-1 differed from those of CD1a-positive abnormal LC-like cells (LCH cells), it was likely that the PRU-1 cells were derived from peripherally located cells of the LCH lesion rather than LCH cells. LCH has been regarded as a type of granulomatous neoplasm with several intermingled inflammatory cells and influenced by stimuli such as Merkel cell polyomavirus (MCPyV) infection or cigarette smoking. However, in the PRU-1 cells, MCPyV-DNA was not detected by PCR. Stromal cell-like PRU-1 cells are likely to produce some growth or differentiation factors, which may play important roles in LCH lesion formation, cell maintenance and LC-like cell induction.

Introduction

Langerhans cell (LC) histiocytosis (LCH) is a disease characterized by the proliferation of CD1a-positive abnormal LC-like cells (LCH cells). The Writing Group of the Histiocyte Society has defined LCH as a single system disease or a multisystem disease (1). Although it has not yet determined whether LCH is a reactive or neoplastic disease, recent data suggest a reactive disorder with an underlying oncogenic potential. In this context, both LCH and pulmonary LCH harbor the BRAF V600E mutation (2,3) and appear to be related to stimuli such as viral infection (4-6) and cigarette smoking (7,8). In addition, it has been reported that the extinction of stimuli may cause spontaneous healing of the LCH disease (9-11).

In terms of LCH as a reactive disease, it has been suggested that viruses might act as causal candidates (6,12-15). Scappaticci et al (16) found that peripheral blood lymphocytes from LCH patients contained chromatin and/or chromosomal breaks, as well as structural chromosomal rearrangements, and concluded that LCH is pathogenetically related to an inherent genetic instability or is caused by environmental viral agents. We recently described the possibility of a causal relationship between Merkel cell polyomavirus (MCPyV) and LCH (4).

Establishment of a cell line derived from an LCH lesion may provide significant information regarding the cell origin and pathogenesis of the disease. In a previous report, we described the establishment of a bone LCH lesion-derived cell line named DOR-1, which showed CD10-positive bone marrow stromal cell characteristics (17). In the present study,

Correspondence to: Dr Ichiro Murakami, Division of Molecular Pathology, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago, Tottori 683-8503, Japan
E-mail: ichiro.murakami.09@gmail.com

Key words: Langerhans cell histiocytosis, cell line, dermal dendritic cell
we report a second cell line named PRU-1, established also from bone LCH, which shows stromal dermal dendritic cell (DDC) characteristics.

Materials and methods

Patient. A lytic lesion developed in the skull of a 7-year-old boy who was biopsied at surgery. Histological analysis confirmed an LCH lesion, which was composed of CD1a+ and S100+ cells that intermingled with inflammatory cells and were surrounded by dense mesenchymal tissue.

Cell culture. A written consent to use the biopsy material for laboratory purposes was obtained from the patient's parents. The cells were then allowed to attach to the culture flask and incubated at 37°C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, L-glutamine and antibiotics (Invitrogen-Life Technologies, Cergy-Pontoise, France). After several days, spindle-shaped cells appeared, which were admixed with macrophage-like cells and lymphocytes. After 5-6 weeks of culture, a mixed cell population, including polygonal and spindle-shaped cells, developed. The culture, which was then named PRU-1, continued growth and proliferation and was passaged at a density of 2x10^5 cells/ml.

Flow cytometry. For two-color flow cytometry, PRU-1 cells (2x10^5) were detached from the culture flask and washed with PBS containing 0.5% bovine serum albumin, followed by incubation with specific antibodies. Non-specific immunolabeling was blocked by treating the cells with heat-inactivated rabbit serum (Sigma-Aldrich). Most of the monoclonal antibodies (mAbs) used were directly conjugated with phycoerythrin or fluorescein isothiocyanate. For the control, isotype-matched irrelevant mAbs at the same dilution as the specific antibodies were used. The stained cells were analyzed on a fluorescence activated cell sorter Calibur flow cytometer (BD Biosciences, San Jose, CA, USA), and data evaluation was performed using the CellQuest software (BD Biosciences).

Immunocytochemistry and special staining of PRU-1 cells. PRU-1 cells were analyzed by immunocytochemistry using the mAbs and polyclonal antibodies listed in Table I. Cytocentrifuge smears, which were prepared after the detachment of adherent PRU-1 cells growing on a culture chamber slide (Falcon; BD Labware, Franklin Lakes, NJ, USA), were fixed in cold acetone for 10 min, rinsed in PBS and incubated with a primary antibody. The specific antibodies were revealed using a polymer-based immunoperoxidase technique (EnVision Plus; DakoCytomation, Glostrup, Denmark). PAS reaction and diastase PAS reaction were conducted.

DNA extraction and analysis of TCRγ rearrangements in the primary LCH lesion and PRU-1 cells. Extraction of DNA from PRU-1 was performed using the proteinase K and phenol/chloroform/isoamyl alcohol (25:24:1 v/v/v) standard procedure. The presence of TCRγ rearrangement in the cells was investi-

Table I. Immunohistochemical analyses of PRU-1, a new cell line derived from a bone LCH lesion.

<table>
<thead>
<tr>
<th>Antibodies against</th>
<th>Clones</th>
<th>Sources</th>
<th>Dilution</th>
<th>Immunoreactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD1a</td>
<td>SK9</td>
<td>BD</td>
<td>1:20</td>
<td>-</td>
</tr>
<tr>
<td>CD10</td>
<td>56C6</td>
<td>Novocastra</td>
<td>1:50</td>
<td>-</td>
</tr>
<tr>
<td>S100</td>
<td>-</td>
<td>Dako Japan</td>
<td>1:1,000</td>
<td>-</td>
</tr>
<tr>
<td>CD11c</td>
<td>3.9</td>
<td>YLEM</td>
<td>1:20</td>
<td>+</td>
</tr>
<tr>
<td>CD14</td>
<td>MφP9</td>
<td>BD Biosciences</td>
<td>1:20</td>
<td>-</td>
</tr>
<tr>
<td>CD34</td>
<td>QBEND-10</td>
<td>Dako Japan</td>
<td>Diluted</td>
<td>-</td>
</tr>
<tr>
<td>CD43</td>
<td>MT1</td>
<td>Euro-Diagnostica AB</td>
<td>1:20</td>
<td>+</td>
</tr>
<tr>
<td>CD54 (ICAM-1)</td>
<td>BBIG-11</td>
<td>Seikagakukogyo</td>
<td>1:1,000</td>
<td>+</td>
</tr>
<tr>
<td>CD56 (NCAM)</td>
<td>123C3</td>
<td>Monosan</td>
<td>1:20</td>
<td>+</td>
</tr>
<tr>
<td>CD68</td>
<td>KP-1</td>
<td>Dako Japan</td>
<td>1:50</td>
<td>+</td>
</tr>
<tr>
<td>CD99 (MIC2)</td>
<td>19</td>
<td>Sigma</td>
<td>1:40</td>
<td>+</td>
</tr>
<tr>
<td>CD106 (αVCAM-1)</td>
<td>BBIG-V1</td>
<td>British Bio Technology</td>
<td>1:1,000</td>
<td>+</td>
</tr>
<tr>
<td>CD141 (thrombomodulin)</td>
<td>1009</td>
<td>Dako Japan</td>
<td>1:25</td>
<td>+</td>
</tr>
<tr>
<td>αSMA</td>
<td>1A4</td>
<td>Dako Japan</td>
<td>1:50</td>
<td>+</td>
</tr>
<tr>
<td>Muscle actin</td>
<td>HHF35</td>
<td>Enzo Diagnostics</td>
<td>1:50</td>
<td>+</td>
</tr>
<tr>
<td>FXIIIa</td>
<td>-</td>
<td>Lab Vision Corporation</td>
<td>10 µg/ml</td>
<td>+</td>
</tr>
<tr>
<td>HLA-DR</td>
<td>DK22</td>
<td>Dako Japan</td>
<td>1:20</td>
<td>-</td>
</tr>
<tr>
<td>Keratin (AE1/3)</td>
<td>AE1/3</td>
<td>Chemicon</td>
<td>1:500</td>
<td>+</td>
</tr>
<tr>
<td>Vimentin</td>
<td>Vim3B4</td>
<td>Dako Japan</td>
<td>1:50</td>
<td>+</td>
</tr>
</tbody>
</table>

LCH, Langerhans cell histiocytosis; αSMA, α-smooth muscle actin. BD Biosciences, San Jose, CA, USA; Chemicon, Temecula, CA, USA; Dako Japan, Kyoto, Japan; Enzo Diagnostics, New York, NY, USA; Immunotech, Marseille, France; Lab Vision Corp., Fremont, CA, USA; Monosan, Uden, The Netherlands; Novocastra, Newcastle upon Tyne, UK; Seikagakukogyo, Tokyo, Japan; Sigma, St. Louis, MO, USA; YLEM, Roma, Italy; Euro Diagnostica AB, Malmö, Sweden.
gated using PCR-amplified DNA from a paraffin-embedded, formalin-fixed original LCH lesion and the proliferating PRU-1 cells following the BIOMED-2 collaboration study protocol (18). PCR products were analyzed using GeneMapper™ software v.3.5 (Applied Biosystems, Foster City, CA, USA).

Electron microscopy (EM). Ultrastructural examination of PRU-1 was performed at different passages after fixation in glutaraldehyde following classical EM protocols of the Okayama University Central Laboratory (Okayama, Japan).

Cytogenetics. PRU-1 metaphases were analyzed according to standard methods of SRL, Inc. (Tachikawa, Tokyo, Japan).

Effects of a conditioned medium from PRU-1 cell culture supernatant on the biology and phenotype of lymphocytes and monocytes from a healthy donor. A conditioned medium was prepared using the supernatant of 1-week cultured PRU-1 cells and diluted with DMEM at a volume ratio of 1:1; this was then used to treat lymphocytes and/or monocytes isolated using a pore filter [0.4-µm pore filter (30-mm Millicell; Nihon Millipore, Tokyo, Japan)]. The conditioned medium from HeLa cell culture was used as the control.

Xenografting into SCID mice. Animal studies were approved by Okayama University Animal Research Laboratory. PRU-1 cells [5×10⁶ cells in 0.2 ml PBS (-)] were injected subcutaneously into five female SCID mice (CB-17 SCID; Okayama University Animal Research Laboratory, Okayama, Japan). The progress of the xenografts was monitored two times a week for 3 months.

Multiplex quantitative real-time PCR (Q-PCR) for MCPyV detection. Multiplex Q-PCR was performed as previously described (4,19).

Results

Histology and immunohistochemistry of the original LCH lesion. Histological examination of hematoxylin and eosin (H&E)-stained sections (Fig. 1A-D) and immunohistochemistry of the initial LCH bone lesion showed the presence of CD1a-positive (Fig. 1E and F) and SI100-positive cells (Fig. 1J and L). Cytokeratin (AE1/3)-positive cells with kidney-like nuclei were distributed across the LCH lesion (Fig. 1H, I and K). Double staining for SI100 and AE1/3 showed the presence of four types of immunoreactive cells within the lesion: SI100+/AE1/3-; SI100-/AE1/3- (green in Fig. 1J and L); SI100+/AE1/3+; SI100-/AE1/3+ (red) intermingled. White scale bar, 100 µm.
S100+/AE1/3+ (red in Fig. 1K and L); and S100+/AE1/3+ (orange in Fig. 1L). Within the peripheral stromal component of the lesion, scattered spindle- or stellate-shaped FXIIIa+ cells (Fig. 1G) and a low number of CD1a+ cells harboring foci (arrowhead) were observed (Fig. 1E).

Establishment of the PRU-1 cell line. Primary cultures obtained after seeding the isolated cells from the LCH infiltrate contained mixed adherent cell populations of variable size and morphology (Fig. 2A). During the second in vitro passage, adherent spindle-shaped cells grew predominantly. One month after initial plating, the proliferating cells could be maintained in DMEM supplemented with 10% fetal calf serum, L-glutamine and antibiotics. After 6 weeks of continuous culture, densely packed adherent cells were further passaged at a density of 2x10^5 cells/ml. The cells continued to grow stably for at least 50 passages. This new cell line, was named PRU-1 (Fig. 2B) and was extensively characterized.

Flow cytometry. The analysis of PRU-1 from the early seventh passage showed that the predominantly expressed molecules were CD14, HLA-ABC, CD58 (leukocyte-function associated molecule-3) and E-cadherin (Fig. 3). LC markers such as CD1a, CD207 (langerin) and CD209 (DC sign; immature DC marker) were negative. CD83 (B cell activation protein; DC marker), CD11b, CD86 [CD152 (CTLA4) ligand; interdigitating cell marker] and CD34 were negative.

Immunophenotype of PRU-1 and a special reaction for glycogen. The immunocytochemical profiles of PRU-1 cells are summarized in Table I. Application of a large panel of antibodies demonstrated that the PRU-1 cells were immunoreactive to CD11c (Fig. 4A), FXIIIa (Fig. 4B), CD43, CD54 (ICAM-1), CD56 (NCAM), CD99 (MIC2), CD106 (aVCAM-1), and CD141 (thrombomodulin), but not to CD1a, CD10, S100, CD14 and CD34 (Fig. 4C). In addition, AE1/3 keratin (Fig. 4D), vimentin, a-smooth muscle actin and muscle actin were expressed. Cytocentrifuge smears of the PRU-1 cells showed the presence of glycogen, as indicated by the positive PAS reaction and confirmed by the diastase PAS reaction.

Analysis of TCRγ in the LCH lesion and PRU-1 cells by PCR. Since TCRγ expansion has been reported in LCH lesions occurring in patients treated for T-lymphoblastic leukemia/lymphoma (20), we determined the TCRγ gene status in both the LCH original tissue and the PRU-1 cells by PCR. GeneMapper™ retrieved only polyclonal bands using the amplified DNA. However, histological analysis of the lesion showed that numerous T cells intermingled with LC cells. No rearrangement of the TCRγ band was detected in the PRU-1 cells.

EM. Various organelles such as the mitochondria, rough ER, Golgi apparatus, and lysosomes were observed in the PRU-1 cells by EM. No Birbeck granules were detected.

Cytogenetic analysis. Repeated karyotype analysis of seven metaphases was performed, which showed male karyotypes consisting of the following constitutions: one metaphase spread showing 39,XY,-2,-4,-8,-12,-12,add(18)(q21),20,+mar, one metaphase spread showing 44,XY,-11,-14,add(18)(q21) (Fig. 5), one metaphase spread showing 44,XY,-10,-14, and four metaphase spreads showing 46,XY. The 18q21 abnormality was detected two times.

Effects of the PRU-1 conditioned medium on the biology and phenotype of lymphocytes and monocytes from a healthy donor. Lymphocytes and monocytes were co-cultured in the PRU-1 conditioned medium. After 7 days of culture in the conditioned medium, the monocytes underwent a change in morphology, resulting in spindle-shaped cells (Fig. 6A and B), whereas some monocytes acquired CD1a positivity (Fig. 6C and D). Lymphocytes cultured in the PRU-1 supernatant showed a higher proliferation rate than the control lymphocytes cultured in a conditioned medium from HeLa cell culture.

Growth in SCID mice. To evaluate whether PRU-1 possessed normal or neoplastic characteristics, we examined the tumorigenicity of the PRU-1 cell line. No tumor growth was detected in the five female SCID mice that were monitored for 3 months.
Q-PCR for MCPyV. No MCPyV DNA sequences were detected in the PRU-1 cell line.

Discussion

Although several studies have established cell lines from LCH lesions, it is generally difficult to retain its full LC characteristics (17,21-23). Previous studies have shown success in short-term culture of LCH tissues; however, these only allowed analyses of cell morphology (24), cytokine production (IL-1 and PGE2) (22), and cell differentiation capacities (23). A few subsequent passages have been achieved, whereas most studies have suggested that LCH cells might have a limited life span in vitro. In the present study, a long-term growing cell line was obtained, which in turn gave rise to the question of whether the PRU-1 cell line was related to the LC lineage or represented an
LC progenitor. LC progenitors are components of multipotent bone marrow-derived stromal cellular compartments that have been implicated in self-perpetuating granulomatous lesions. Thus, the immunocytochemical profile, namely the FXIIIa positivity and the absence of CD34 expression and distinct cytoplasmic Birbeck granules, were a priori consistent with a DDC origin for the PRU-1 cells. It was previously reported that CD1a-positive DCs from peripheral blood mononuclear cells could differentiate into any of the three cell types: histioocyte DC-like cells (FXIIIa+++), fibroblast-like cells (FXIIIa++), and giant cell-like cells (FXIIIa+) (25). In fact, fibroblast-like FXIIIa⁺ DDC is the cell type that typically proliferates in dermatofibromas. In this regard, PRU-1 exhibited phenotypic characteristics of fibroblast-like DDCs in terms of FXIIIa positivity and its spindle-shaped cellular morphology. In addition, EM analysis showed that PRU-1 harbored numerous organelles. Similarly, dermatofibroma tumoral cells show well-developed rough ER, conspicuous Golgi apparatus, and a variable number of mitochondria (26). These features thus suggested that PRU-1 might be a clonal expansion derived from FXIIIa⁺ stellate cells present in the fibrous area of the original lesion.

The PRU-1 cells also expressed cytokeratin (AE1/3=cytokeratin 1-8/10/14/15/16/19) (Table I). The original LCH lesions systematically showed scattered keratin-positive cells (Fig. 1H-L). Double staining indicated that the LCH lesion contained a mixture of S100⁺/AE1/3⁺, S100⁺/AE1/3⁺, S100⁺/AE1/3⁺ and S100⁺/AE1/3⁻ cells. Bone LCH has a self-
limiting tendency and develops into scar-like granuloma with the accumulation of a mixture of foamy cells and macrophages (27). One of the important questions that needs to be answered is the origin of LCH cells. The presence of S100+/AE1/3+ cells raises the question of whether the AE1/3+ cells originate from typical LCH cells or from other cell types that comprise the LCH lesion. Keratin is present in the cellular cytoskeleton, and cytokeratin+ cells could produce cytokine (28) with admixed cells in the LCH lesion (29). PRU-1 phenotypically consisted of S100-, AE1/3+ and FXIIIa+ cells. Moreover, scattered FXIIIa+ cells were detected in the peripheral fibrous area of the original LCH lesion (Fig. 1G). In general, it is accepted that LC is derived from an LC precursor through an immature cell type and that LC can differentiate into interdigitating cells through veiled cells (30). Similarly, DDCs seem to have been derived from a cellular precursor that has differentiated into DCs or LCs. There are data indicating that LCs are incapable of differentiating into the DDC type (31). We think PRU-1 was derived from stromal cell types that comprised the LCH lesion.

It has been suggested that some LCH cells are derived from the T cell lineage with TCRγ monoclonality (20), although a diverse collection of data exists. Our PCR results allowed the characterization of the polyclonal TCRγ genomic structure of the PRU-1 original tissue, as well as indicated the absence of TCRγ monoclonality in the PRU-1 cells. These data showed the presence of polyclonal T cells in the LCH original tissue and that PRU-1 elements did not originate from the T cell lineage.

Cytogenetic analyses of PRU-1 showed the presence of an 18q21 chromosomal abnormality. We recently described the possibility of a causal relationship between MCPyV and LCH (4) and Scappaticci et al (16) found that peripheral blood lymphocytes from LCH patients contained chromosomal abnormality and pointed out that LCH was caused by environmental viral agents. The 18q21 abnormality which was detected two times may also indicate a clonal proliferation of PRU-1 cells and the effect of viral infection as shown in blood lymphocytes by Scappaticci et al (16). In this context, chromosomal rearrangements have been detected in a few LCH cases (32,33), as well as in pulmonary LCH which is thought to be a reactive and neoplastic disorder caused by cigarette smoking (2,7). Familial clustering suggesting a genetic event in LCH has also been reported (6,34-36).

To assess cytokine production, the conditioned medium was added to the monocyte and lymphocyte cultures (37) as well as to lymphocytes or monocytes from a healthy donor. Observed phenotypic changes included some CD1a- monocytes transforming into CD1a+ cells and a high proliferation rate compared with that of the control. These findings suggest that the PRU-1 cultured cells produced stimulatory growth or differentiation factors that have yet to be fully characterized.

Analysis of specific chromosomal aberrations using the PRU-1 in vitro model and conditioned medium might also provide new insights on LCH pathogenesis, i.e. LCH microenvironment contributed by stromal cells.

We recently described the relationship between MCPyV and LCH (4) and hypothesized that LCH was a reactive disorder with an underlying oncogenic potential. Extinction of stimuli such as MCPyV infection could cause spontaneous healing of LCH, although MCPyV has been considered as a potential neoplastic agent for Merkel cell carcinoma (38). However, in the PRU-1 cells, MCPyV DNA was not detected and was not likely to contribute to the cell line establishment, although the genomic instability of PRU-1 cells might be induced by MCPyV infection (16).
Finally, the LCH lesion is a mixture of various cells, including LC-like cells, DDC-like cells, macrophages, lymphocytes, neutrophils, lymphocytes and eosinophils. We were successful in establishing a CK+ / S100+ cell line, PRU-1, from a bone LCH lesion that retains DDC-like characteristics such as CD11c, CD54 and CD141 immunoreactivity, in addition to FXIII A expression. The PRU-1 conditioned medium may contain yet unknown specific molecules that may contribute to the formation of LCH lesions, as well as facilitate in induction studies using CD1a+ or LCH cells.

Acknowledgements
The authors are indebted to Ms. Masumi Furutani (Central Laboratory, Okayama University) for her help in performing EM analysis.

References